In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What next for Guidant and J&J?

Executive Summary

With the announced launch of a criminal investigation into Guidant's marketing practices by the New York State Attorney General's office and an SEC inquiry into product disclosures and Guidant's stock trading coming on the heels of the clearance of the deal by the Federal Trade Commission (FTC), news reports seemed divided on whether the $25.4 billion mega-merger of Guidant Corp. and Johnson & Johnson was actually going to take place. Some industry analysts said the deal was essentially dead; others cited analysts just as certain that the deal would get done in some form or another.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts